';
CLOSE
Tags Posts tagged with "OUD"

OUD

0 1334

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) announced the availability of $9 million in funding to expand or enhance recovery support services for individuals in recovery from opioid use disorder (OUD) and other substance use disorders (SUD).

DDAP will award approximately six grants of up to $1.5 million each. Applicants must have at least two years of experience as of July 1, 2024, in providing recovery support services and be able to demonstrate the capacity to provide those services to individuals in recovery from OUD and other concurrent SUDs.

DDAP is placing a focus on health equity as a part of this grant opportunity. Based on a variety of criteria from the Pennsylvania Department of Health’s 2022 overdose death data, DDAP will select two grantees located in Philadelphia, two grantees located in Allegheny County, and two grantees from the remaining 19 qualifying counties located within Pennsylvania with a crude death rate higher than the state average.

Funding for these grants is provided through the federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Opioid Response (SOR) IV grant program. The SOR program aims to help reduce unmet treatment needs and opioid-related overdose deaths nationwide through state-by-state allocations.

Read the full press release.

You can send questions electronically regarding the grants and the application process.

0 827

The Pennsylvania Department of Health (PA DOH) is currently accepting applications for the PA-SUN Request for Applications (RFA). Hospitals and Health Systems, on behalf of their ED(s), are invited to apply to the Department in accordance with RFA # 67-166.

The Department is interested in funding applications addressing building and implementing health system-wide clinical capacity to screen, diagnose, and support longitudinal care for opioid use disorder (OUD) and stimulant use disorder (StUD) as well as support recovery for adults and adolescents.

The overall goal of this funding is to promote and support ED linkage to care via multidisciplinary teams utilizing navigators, to include strategies like focused connections during care for conditions that may represent sequelae of substance use and enhanced universal screening for substance use disorder (SUD) among patients presenting for other reasons to EDs to identify new opportunities to engage in and link to care.

All questions regarding this RFA must be directed via email, no later than 12:00 pm on December 4, 2023. All questions must include the specific section of the RFA about which the potential applicant is requesting clarification. Answers to all questions will be posted on PA eMarketplace. To review the responses to posed questions, select ‘Solicitations’ and search for RFA #67-166. Applications must be received no later than 1:30 pm on January 16, 2024.

An additional update regarding the educational modules: By end of year 2023, the PA-SUN team intends to release asynchronous (self-study) education modules to aid EDs in increasing knowledge on topics such as harm reduction, buprenorphine initiation, linkage to care, and stigma.  For updates regarding the education modules please visit the PA-SUN website.

0 850

RCPA SUD Treatment Services Policy Director Jason Snyder will testify on Thursday, March 9, at the Center for Rural Pennsylvania’s hearing, “New Developments in the Opioid and Substance Use Disorder Crisis in Rural Pennsylvania.”

Snyder will testify on a panel that will examine SUD treatment workforce and regulation. Justin Wolford, Director of Outpatient Services at RCPA member CenClear, also will testify on the panel. Wolford will focus on the workforce crisis, while Snyder will discuss regulations that exacerbate the crisis and should be reformed.

The hearing will be comprised of four total panels:

  • Developments in the Supply of Narcotics;
  • Data Resources;
  • Funding and Programming; and
  • Workforce and Regulations.

The hearing begins at 9:00 am and will take place in the Main Capitol Building, Room 8E-B, in Harrisburg. It also will be livestreamed online.

0 977

The Drug Enforcement Agency (DEA) is proposing to roll back flexibilities implemented during the public health emergency (PHE) in tele-prescribing buprenorphine. The proposed new regulation would mandate an initial in-person visit with a prescriber in order for a patient to receive more than a 30-day buprenorphine prescription. Since 2020, those with opioid use disorder have been able to receive prescriptions for buprenorphine, including the initial prescription, following a tele-appointment.

Patients who began buprenorphine treatment during the PHE under the expanded flexibilities would have a 180-day grace period but would then need to see a prescriber in person before continuing treatment under the DEA’s proposed rule.

The proposed rule and instructions for providing comments are available online. The public comment period closes March 31, 2023.

12Next Page 1 of 2
© 2021 - Rehabilitation & Community Providers Association